...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs: International Journal of Current Therapeutics and Applied Pharmacology Reviews, Featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts >Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
【24h】

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives

机译：针对神经内分泌肿瘤的靶向全身治疗：当前的选择和未来的观点

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical syndromes. Systemic treatment of patients with unresectable NETs aims to control symptoms related to hormonal overproduction and tumor growth. In the last decades prognosis has improved as a result of increased detection of early stage disease and the introduction of somatostatin analogs (SSAs) as well as several new therapeutic options. SSAs are the first-line medical treatment of NETs and can control hormonal production and tumor growth. The development of next-generation multireceptor targeted and radiolabelled somatostatin analogs, as well as target-directed therapies (as second-line treatment options) further improve progression-free survival in NET patients. To date, however, a significant prolongation of overall survival with systemic treatment in NET has not been convincingly demonstrated. Several new medical options and treatment combinations will become available in the upcoming years, and although preliminary results of preclinical and clinical trials are encouraging, large, preferrably randomized clinical studies are required to provide definitive evidence of their effect on survival and symptom control.
机译：神经内分泌肿瘤（网）源自支气管和胃肠道中的神经内分泌细胞系统，可以产生导致临床综合征的激素。系统治疗患者不可切除的网症旨在控制与激素过产和肿瘤生长有关的症状。在过去几十年中，由于早期疾病的检测和生长抑素类似物（SSAS）以及几种新的治疗选择，预后提高了改善。 SSA是蚊帐的一线医疗，可控制荷尔蒙生产和肿瘤生长。下一代多人靶向和放射性标记的生长抑素类似物的发展，以及靶向治疗（作为第二线治疗方案）进一步改善净患者的无进展生存期。然而，迄今为止，在网中全身治疗的整体存活率显着延长并未令人信服地证明。即将到来的几年，几个新的医疗选择和治疗组合将可用，尽管临床前和临床试验的初步结果是令人鼓舞的，但是需要大，优选的随机临床研究，以提供对生存和症状控制影响的明确证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号